Middle East Journal of Rehabilitation and Health

Published by: Kowsar

Inhibitory Effects of Silica Nanoparticles Loaded with Hematoporphyrin on Breast Cancer Cell Line

Ali Khaleghian 1 , Hadi Hasanzadeh 2 , * , Abdolvahab Moshtaghian 3 , Reza Nasr 4 , Alireza Emadi 3 and Shima Moshfegh 5
Authors Information
1 Department of Biochemistry, Semnan University of Medical Sciences, Semnan, Iran
2 Cancer Research Center and Department of Medical Physics, Semnan University of Medical Sciences, Semnan, Iran
3 Deputy of Research and Technology, Semnan University of Medical Sciences, Semnan, Iran
4 Biotechnology Research Center, Semnan University of Medical Sciences, Semnan, Iran
5 Student Research Committee, Department of Medical Physics, Semnan University of Medical Sciences, Semnan, Iran
Article information
  • Middle East Journal of Rehabilitation and Health: July 2018, 5 (3); e64843
  • Published Online: June 23, 2018
  • Article Type: Research Article
  • Received: December 6, 2017
  • Revised: May 19, 2018
  • Accepted: May 20, 2018
  • DOI: 10.5812/mejrh.64843

To Cite: Khaleghian A, Hasanzadeh H, Moshtaghian A, Nasr R, Emadi A, et al. Inhibitory Effects of Silica Nanoparticles Loaded with Hematoporphyrin on Breast Cancer Cell Line, Middle East J Rehabil Health Stud. 2018 ; 5(3):e64843. doi: 10.5812/mejrh.64843.

Abstract
Copyright © 2018, Middle East Journal of Rehabilitation and Health Studies. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
Footnotes
References
  • 1. Dolat E, Hasanzadeh H, Rezaei Tavirany M, Heidari keshel S, Jabbari Arfaee A, Seyyedi SS. [Evaluation of synergistic effect of TiO2 nanoparticles and gamma rays on human breast cancer cell line]. J Ilam Univ Med Sci. 2013;20(4):223-30. Persian.
  • 2. Esmaeillou M, Moharamnejad M, Hsankhani R, Tehrani AA, Maadi H. Toxicity of ZnO nanoparticles in healthy adult mice. Environ Toxicol Pharmacol. 2013;35(1):67-71. doi: 10.1016/j.etap.2012.11.003. [PubMed: 23262039].
  • 3. Rezaei-Tavirani M, Dolat E, Hasanzadeh H, Seyyedi SS, Semnani V, Sobhi S. TiO2 Nanoparticle as a sensitizer drug in radiotherapy: in vitro study. Iran J Cancer Prev. 2013;6:37-44.
  • 4. Tang F, Li L, Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater. 2012;24(12):1504-34. doi: 10.1002/adma.201104763. [PubMed: 22378538].
  • 5. Lin W, Huang YW, Zhou XD, Ma Y. In vitro toxicity of silica nanoparticles in human lung cancer cells. Toxicol Appl Pharmacol. 2006;217(3):252-9. doi: 10.1016/j.taap.2006.10.004. [PubMed: 17112558].
  • 6. Liberman A, Martinez HP, Ta CN, Barback CV, Mattrey RF, Kono Y, et al. Hollow silica and silica-boron nano/microparticles for contrast-enhanced ultrasound to detect small tumors. Biomaterials. 2012;33(20):5124-9. doi: 10.1016/j.biomaterials.2012.03.066. [PubMed: 22498299]. [PubMed Central: PMC3588157].
  • 7. Hassankhani R, Esmaeillou M, Tehrani AA, Nasirzadeh K, Khadir F, Maadi H. In vivo toxicity of orally administrated silicon dioxide nanoparticles in healthy adult mice. Environ Sci Pollut Res Int. 2015;22(2):1127-32. doi: 10.1007/s11356-014-3413-7. [PubMed: 25113834].
  • 8. Garcia-Bennett AE. Synthesis, toxicology and potential of ordered mesoporous materials in nanomedicine. Nanomedicine (Lond). 2011;6(5):867-77. doi: 10.2217/nnm.11.82. [PubMed: 21793677].
  • 9. Watermann A, Brieger J. Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer. Nanomaterials (Basel). 2017;7(7). doi: 10.3390/nano7070189. [PubMed: 28737672]. [PubMed Central: PMC5535255].
  • 10. Kwon S, Singh RK, Perez RA, Abou Neel EA, Kim HW, Chrzanowski W. Silica-based mesoporous nanoparticles for controlled drug delivery. J Tissue Eng. 2013;4:2.0417314135034E+15. doi: 10.1177/2041731413503357. [PubMed: 24020012]. [PubMed Central: PMC3764983].
  • 11. Bharti C, Nagaich U, Pal AK, Gulati N. Mesoporous silica nanoparticles in target drug delivery system: A review. Int J Pharm Investig. 2015;5(3):124-33. doi: 10.4103/2230-973X.160844. [PubMed: 26258053]. [PubMed Central: PMC4522861].
  • 12. Chung TH, Wu SH, Yao M, Lu CW, Lin YS, Hung Y, et al. The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials. 2007;28(19):2959-66. doi: 10.1016/j.biomaterials.2007.03.006. [PubMed: 17397919].
  • 13. Milgroom A, Intrator M, Madhavan K, Mazzaro L, Shandas R, Liu B, et al. Mesoporous silica nanoparticles as a breast-cancer targeting ultrasound contrast agent. Colloids Surf B Biointerfaces. 2014;116:652-7. doi: 10.1016/j.colsurfb.2013.10.038. [PubMed: 24269054]. [PubMed Central: PMC4687408].
  • 14. Coti KK, Belowich ME, Liong M, Ambrogio MW, Lau YA, Khatib HA, et al. Mechanised nanoparticles for drug delivery. Nanoscale. 2009;1(1):16-39. doi: 10.1039/b9nr00162j. [PubMed: 20644858].
  • 15. Mamaeva V, Sahlgren C, Linden M. Mesoporous silica nanoparticles in medicine--recent advances. Adv Drug Deliv Rev. 2013;65(5):689-702. doi: 10.1016/j.addr.2012.07.018. [PubMed: 22921598].
  • 16. Yang KN, Zhang CQ, Wang W, Wang PC, Zhou JP, Liang XJ. pH-responsive mesoporous silica nanoparticles employed in controlled drug delivery systems for cancer treatment. Cancer Biol Med. 2014;11(1):34-43. doi: 10.7497/j.issn.2095-3941.2014.01.003. [PubMed: 24738037]. [PubMed Central: PMC3969802].
  • 17. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60(15):1615-26. doi: 10.1016/j.addr.2008.08.005. [PubMed: 18840489].
  • 18. Taratula O, Garbuzenko OB, Chen AM, Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target. 2011;19(10):900-14. doi: 10.3109/1061186X.2011.622404. [PubMed: 21981718].
  • 19. Chen AM, Zhang M, Wei D, Stueber D, Taratula O, Minko T, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small. 2009;5(23):2673-7. doi: 10.1002/smll.200900621. [PubMed: 19780069]. [PubMed Central: PMC2833276].
  • 20. Ngamcherdtrakul W, Morry J, Gu S, Castro DJ, Goodyear SM, Sangvanich T, et al. Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer. Adv Funct Mater. 2015;25(18):2646-59. doi: 10.1002/adfm.201404629. [PubMed: 26097445]. [PubMed Central: PMC4469082].
  • 21. Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small. 2010;6(16):1794-805. doi: 10.1002/smll.201000538. [PubMed: 20623530]. [PubMed Central: PMC2952648].
  • 22. He X, Nie H, Wang K, Tan W, Wu X, Zhang P. In vivo study of biodistribution and urinary excretion of surface-modified silica nanoparticles. Anal Chem. 2008;80(24):9597-603. doi: 10.1021/ac801882g. [PubMed: 19007246].
  • 23. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer. 2011;12(1):39-50. doi: 10.1038/nrc3180. [PubMed: 22193407].
  • 24. U.S. Department of Health and Human Services , National Institutes of Health , National Cancer Institute . hematoporphyrin derivative. 2017. Available from: https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=40859.
  • 25. ATCC . MCF7 (ATCC® HTB-22™). 2017. Available from: https://www.atcc.org/Products/All/HTB-22.aspx.
  • 26. Vazquez NI, Gonzalez Z, Ferrari B, Castro Y. Synthesis of mesoporous silica nanoparticles by sol–gel as nanocontainer for future drug delivery applications. Bol Soc Esp Ceram V. 2017;56(3):139-45. doi: 10.1016/j.bsecv.2017.03.002.
  • 27. Gary-Bobo M, Hocine O, Brevet D, Maynadier M, Raehm L, Richeter S, et al. Cancer therapy improvement with mesoporous silica nanoparticles combining targeting, drug delivery and PDT. Int J Pharm. 2012;423(2):509-15. doi: 10.1016/j.ijpharm.2011.11.045. [PubMed: 22178618].
  • 28. Kim KA, Kim YH, Seok Seo M, Kyu Lee W, Won Kim S, Kim H, et al. Mechanism of silica-induced ROS generation in Rat2 fibroblast cells. Toxicol Lett. 2002;135(3):185-91. doi: 10.1016/S0378-4274(02)00237-0. [PubMed: 12270676].
  • 29. You DG, Deepagan VG, Um W, Jeon S, Son S, Chang H, et al. ROS-generating TiO2 nanoparticles for non-invasive sonodynamic therapy of cancer. Sci Rep. 2016;6:23200. doi: 10.1038/srep23200. [PubMed: 26996446]. [PubMed Central: PMC4800401].
  • 30. Taylor KM, Kim JS, Rieter WJ, An H, Lin W, Lin W. Mesoporous silica nanospheres as highly efficient MRI contrast agents. J Am Chem Soc. 2008;130(7):2154-5. doi: 10.1021/ja710193c. [PubMed: 18217764].
  • 31. Liu HM, Wu SH, Lu CW, Yao M, Hsiao JK, Hung Y, et al. Mesoporous silica nanoparticles improve magnetic labeling efficiency in human stem cells. Small. 2008;4(5):619-26. doi: 10.1002/smll.200700493. [PubMed: 18491363].
  • 32. Maadi H, Moshtaghian A, Taha MF, Mowla SJ, Kazeroonian A, Haass NK, et al. Multimodal tumor suppression by miR-302 cluster in melanoma and colon cancer. Int J Biochem Cell Biol. 2016;81(Pt A):121-32. doi: 10.1016/j.biocel.2016.11.004. [PubMed: 27840154].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments